Embecta (EMBC) Expected to Announce Quarterly Earnings on Friday

Embecta (NASDAQ:EMBC - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Friday, May 9th. Analysts expect Embecta to post earnings of $0.66 per share and revenue of $261.77 million for the quarter. Embecta has set its FY 2025 guidance at 2.700-2.900 EPS.

Embecta (NASDAQ:EMBC - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.65 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.45 by $0.20. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. On average, analysts expect Embecta to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Embecta Stock Up 0.7 %

Embecta stock opened at $12.28 on Friday. Embecta has a 52-week low of $10.10 and a 52-week high of $21.48. The firm has a market capitalization of $713.89 million, a price-to-earnings ratio of 12.28, a PEG ratio of 0.78 and a beta of 1.23. The company has a fifty day simple moving average of $12.54 and a 200-day simple moving average of $15.79.

Embecta Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, March 14th. Stockholders of record on Friday, February 28th were issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 4.89%. The ex-dividend date was Friday, February 28th. Embecta's payout ratio is 60.00%.

Analyst Upgrades and Downgrades

Separately, Mizuho began coverage on shares of Embecta in a research report on Thursday, April 10th. They set a "neutral" rating and a $15.00 price target on the stock.

Insider Buying and Selling at Embecta

In other Embecta news, Director Milton Mayo Morris sold 3,100 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $16.38, for a total value of $50,778.00. Following the transaction, the director now owns 36,133 shares of the company's stock, valued at $591,858.54. This represents a 7.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.42% of the stock is currently owned by corporate insiders.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.